Loading clinical trials...
Loading clinical trials...
A Phase 2b, Open-label, Single-arm, Multi-centre Study Assessing the Efficacy and Safety of Adavosertib as Treatment for Recurrent or Persistent Uterine Serous Carcinoma
Conditions
Interventions
Adavosertib
Locations
27
United States
Research Site
Burbank, California, United States
Research Site
Duarte, California, United States
Research Site
La Jolla, California, United States
Research Site
West Hollywood, California, United States
Research Site
Aurora, Colorado, United States
Research Site
Iowa City, Iowa, United States
Start Date
November 30, 2020
Primary Completion Date
May 23, 2022
Completion Date
February 7, 2023
Last Updated
August 14, 2023
Lead Sponsor
AstraZeneca
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions